PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	10/806,295
Filing Date	March 22, 2004
First Named Inventor	LaColla, *et al.*
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	06171.105033 IDX 1008 DIV

3463446_2.DOC

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. [1]	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
GM	AA	4,866,084	A	Gunasekera *et al.*	09-12-1989	
	AB	5,124,327	A	Greenlee *et al.*	06-23-1992	
	AC	5,489,685	A	Houpis *et al.*	02-06-1996	
	AD	5,527,819	A	Williams *et al.*	06-18-1996	
	AE	5,830,894	A	Pevear *et al.*	11-03-1998	
	AF	5,852,011	A	Matsunaga *et al.*	12-22-1998	
	AG	5,929,114	A	Domagala *et al.*	07-27-1999	
	AH	5,935,982	A	Dykstra *et al.*	08-10-1999	
	AI	5,945,440	A	Kleinschroth *et al.*	08-31-1999	
	AJ	5,981,525	A	Farina *et al.*	11-09-1999	
	AK	6,025,390	A	Farina *et al.*	02-15-2000	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. [1]	Foreign Patent Document Office [3]	Number	Kind Code [4] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [6]
GM	AL	EP	0,530,907	A1	Merck & Co.	03-10-1993		
~~—~~	~~AM~~	~~WO~~	~~94/19321~~	~~A1~~	~~Merck & Co.; Theoharides~~	~~09-01-1994~~		
GM	AN	WO	02/083126	A1	Idenix; Univ. Degli Studi di Cagliari	10-24-2002		
GM	AO	WO	04/014364	A1	Idenix	02-19-2004		

NOT present

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. [1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [6]
GM	AP	BALANI, S.K., *et al.*, "Biotransformation of 5-chloro-3-phenylthioindole-2-carboxamide (L-734,005) in rhesus monkeys and rat liver microsomes to a potent HIV-1 reverse transcriptase inhibitor," *Drug Metab. Dispso.*, 21(4):598-604 (July-August 1993).	

Examiner Signature	Gregory T. Mutter	Date Considered	10/28/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	2	of	2

Complete if Known	
Application Number	10/806,295
Filing Date	March 22, 2004
First Named Inventor	LaColla, *et al.*
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	06171.105033 IDX 1008 DIV

3463446_2.DOC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. [1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	AQ	CLAUSON-KAAS, N., *et al.*, "Preparation of *Cis* and *Trans* 2,5-Dimethoxy-2-(acetamidomethyl)-2,5-dihydrofuran, of *Cis* and *Trans* 2,5-Dimethoxy-2-(acetamidomethyl)-tetrahydrofuran and of 1-Phenyl-2-(acetamidomethyl)pyrrole," *Acta Chem. Scand.*, 6:667-670 (1952).	
	BA	ELMING, N., *et al.*, "The preparation of pyrroles from furans," *Acta Chem. Scand.*, 6:867-874 (1952).	
	BB	GAGLIARDI, S., *et al.*, "5-(5,6-Dichloro-2-indolyl)-2-methoxy-2,4-pentadienamides: novel and selective inhibitors of the vacuolar H+-ATPase of osteoclasts with bone antiresorptive activity," *J. Med. Chem.*, 41(10):1568-1573 (May 7, 1998).	
	BC	PAUWELS, R., *et al.*, "Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives," *Nature*, 343(6257):470-474 (February 1, 1990).	
	BD	PAUWELS, R., *et al.*, "Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase," *Proc. Natl. Acad. Sci. USA*, 90(5):1711-1715 (March 1, 1993).	
	BE	PHILLIPS, R.R., "The Japp-Klingemann Reaction," *Org. Reactions*, 10:143-178 (1959).	
	BF	ROMERO, D.L., *et al.*, "Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3-[(1-methylethyl)amino]-pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate," *J. Med. Chem.*, 36(10):1505-1508 (May 14, 1993).	
	BG	WILLIAMS, T.M., *et al.*, "5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase, *J. Med. Chem.*, 36(9):1291-1294 (April 30, 1993)	

Not present

Examiner Signature		Date Considered	10/28/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.